He is the Chief of Hematology/Oncology, co-director of the BU/BMC Cancer Center and "Zoltan Kohn Professor" at the Boston University School of Medicine.
[2][3] His work has shed light on the molecular characteristics of neuroendocrine tumors and has led to the development of multiple new treatments for this condition.
[4][5] His research studies led to the development and approval of telotristat ethyl, a tryptophan hydroxylase inhibitor,[6] for the treatment of patients with carcinoid syndrome.
[7] He has also contributed to early and late stage clinical trials of temozolomide, sunitinib,[8] everolimus, and peptide receptor radiotherapy for neuroendocrine tumors.
[10] After his education, Kulke subsequently joined the faculty at Dana-Farber Cancer Institute and Harvard Medical School[11] where he rose to the rank of Professor of Medicine and was the founding director of the neuroendocrine tumor program.